Meet Tesla BioscienceTM.
We invent, develop, produce…



Our experts led by Dr Dusan Ninkov PhD invented the best solutions for worldwide clinical medicine problems.


Experienced and dedicated pharmacists and bioscientists care about development.


The production and distribution of our products is controlled by TeslaBioscienceTM team.

Conducting wide range research and development for novel medicine, providing it for worldwide trials followed by global registration and production is our pathway to bring new values in science and lives. RnD for humankind, to serve health.

From a global perspective, infectious diseases are the second leading cause of death and the leading cause of disability. Nosocomial infectious diseases are the major cause of tragically complex infectious diseases in the 21st century, in both developed and developing nations.

Current antibiotic therapy for nosocomial infections is also facing worsening antimicrobial resistance. The number of new antibiotics made to combat resistant infectious bacterias have declined over the years.

Current antibiotics such as penicillin, oxacillin, methicillin and macrolide-based antibiotics also treat bacterial infections but are powerless against microbes, which have developed a resistance against these traditional therapies.

Currently, there are incredible challenges for developing new antibiotic therapies that address this and other infectious diseases. The global medical community is constantly in search of new pharmaceutical products to protect the lives of patients around the globe.




There is a huge demand worldwide for research and development of new medicines, different than antibiotics, which do not allow the resistance by pathogens to be built up, specifically for treating sepsis, nosocomial infections, opportunistic infections and fungal infections.

Tesla BioScience progress path is the toward development of new medicine therapies that address these and other infectious diseases caused by:

- Methicillin-resistant Staphylococcus aureus (MRSA)
- Streptococcus faecalis
- Escherichia coli 0157H
- Salmonella typhimurium
- Mycobacterium tuberculosis



Patents in the process:

1. A novel pharmaceutical compounds with a novel
method of synthesis for the treatment of bacterial
infections in humans.

2. A novel pharmaceutical compound with a novel
method of synthesis for the treatment of tuberculosis
in humans.

3. A novel pharmaceutical compound with a novel
method of synthesis which has an antiviral effect for the
treatment of viral infections in humans.